Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

tend to disagree,did you read the quarterly as its on track for testing glaucoma,with r+d refund 5 mil in the bank more than the market cap.
NSB is working with a highly experienced and qualified regulatory consultancy that holds
offices in UK, EU, US and Australia, to ensure that NSB can gain as much insight from the FDA
and confirm that the development plan in place for EmtinB within Ophthalmology is within
the regulator's expectations to allow the initiation of a clinical trial.
It is expected that this submission will occur in Q1 2024.

Currently a buy for me again